NASDAQ · QDEL
QuidelOrtho Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for QDEL: Nov 03, 2026
QuidelOrtho Corporation Common Stock is expected to report earnings on 11/03/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $0.18. The reported EPS for the same quarter last year was $0.8.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.18 | $0.18 | $0.18 | 1 |
| Dec 2026 | $0.47 | $0.47 | $0.47 | 1 |
| Mar 2027 | $0.01 | $0.01 | $0.01 | 1 |
| Jun 2027 | $0.11 | $0.11 | $0.11 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · BNK Invest · The Motley Fool · MarketBeat- Zacks · Oct 14, 9:38 AM EDTReasons to Add QuidelOrtho Stock to Your Portfolio for NowQDEL's strong Q2 results, diversified product portfolio and cost-saving initiatives bolster its growth prospects despite persistent weakness in respiratory demand.
- BNK Invest · Oct 14, 6:52 AM EDTQuidelOrtho Reaches Analyst Target PriceIn recent trading, shares of QuidelOrtho Corp (Symbol: QDEL) have crossed above the average analyst 12-month target price of $13.50, changing hands for $14.10/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on val
- Zacks · Aug 24, 10:16 AM EDTHere's What Is Shaping Abbott's Diagnostics GrowthABT's Diagnostics growth is being reshaped as weaker respiratory testing offsets healthy routine demand and 13% cancer diagnostics growth.
- Zacks · Aug 17, 2:05 PM EDTQDEL's 2026 Outlook Cut Deepens China and Respiratory Risk ConcernsQuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.
- Zacks · Aug 17, 1:56 PM EDTIs QDEL Worth Buying as China Risks Clash With Resilient Core Growth?QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.
- Zacks · Aug 17, 1:46 PM EDTQDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.
- The Motley Fool · Aug 13, 8:16 PM EDTQuidelOrtho (QDEL) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 10, 1:29 PM EDTQDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance LoweredQuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.
- Zacks · Aug 7, 10:49 AM EDTHere's How ABT Broadens Diagnostics Growth Base With Oncology ExpansionAbbott broadens Diagnostics growth with Exact Sciences, as Cancer Diagnostics gains and resilient routine testing offset respiratory weakness.
- MarketBeat · Aug 7, 6:03 AM EDTQuidelOrtho Q2 Earnings Call HighlightsLucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11QuidelOrtho (NASDAQ:QDEL) reported second-quarter revenue growth despite continued pressure from China and a softer respiratory testing environment, while lowering its full-year outlook and withdrawing free cash flow
- Zacks · Aug 6, 5:20 PM EDTQuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue EstimatesQuidelOrtho (QDEL) delivered earnings and revenue surprises of +425.00% and +2.65%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 11:35 AM EDTImplied Volatility Surging for QuidelOrtho Stock OptionsInvestors need to pay close attention to QDEL stock based on the movements in the options market lately.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for QuidelOrtho Corporation from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.